Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 28 Issue 6
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2010  >  28(6): 451-455

ZHANG Qi, XIA Ai-jun. Meta-analysis of combining rh-endostatin with chemotherapy in treatment of NSCLC[J]. Journal of Pharmaceutical Practice and Service, 2010, 28(6): 451-455.
Citation: ZHANG Qi, XIA Ai-jun. Meta-analysis of combining rh-endostatin with chemotherapy in treatment of NSCLC[J]. Journal of Pharmaceutical Practice and Service, 2010, 28(6): 451-455.
shu

Meta-analysis of combining rh-endostatin with chemotherapy in treatment of NSCLC

  • Department of pharmacy,303 hospital of PLA,Nanning 530021,China

  • Received Date: 2010-04-02
  • Rev Recd Date: 2010-04-02
  • Objective To evaluate the efficacy of combining rh-endostatin with chemotherapy for non-small cell lung cancer(NSCLC) compared with chemotherapy alone. Methods The literature of randomized clinical trials(RCTs) that compared the efficacy of combining rh-endostatin with chemotherapy and chemotherapy alone form 2000 to 2009 were collected.Meta-analysis was employed to evaluate the Results of these therapies by RevMan 4.2.11 literature was seclected including 915 cases. Results Compared with control group,the total OR of efficiency rate of combining rh-endostatin with chemotherapy was 2.49,(95%CI,1.83-3.40),OR of the disease control rate were 1.91,(95%CI,1.40-2.59),both showing significant difference(P<0.01). Conclusion Combining rh-endostatin with chemotherapy was superior to chemotherapy alone in treatment of NSCLC in total efficiency rate and disease control rate.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(2277) PDF downloads(308) Cited by()

Related
Proportional views

Meta-analysis of combining rh-endostatin with chemotherapy in treatment of NSCLC

  • Department of pharmacy,303 hospital of PLA,Nanning 530021,China
  • Received Date: 2010-04-02
  • Rev Recd Date: 2010-04-02

Abstract: Objective To evaluate the efficacy of combining rh-endostatin with chemotherapy for non-small cell lung cancer(NSCLC) compared with chemotherapy alone. Methods The literature of randomized clinical trials(RCTs) that compared the efficacy of combining rh-endostatin with chemotherapy and chemotherapy alone form 2000 to 2009 were collected.Meta-analysis was employed to evaluate the Results of these therapies by RevMan 4.2.11 literature was seclected including 915 cases. Results Compared with control group,the total OR of efficiency rate of combining rh-endostatin with chemotherapy was 2.49,(95%CI,1.83-3.40),OR of the disease control rate were 1.91,(95%CI,1.40-2.59),both showing significant difference(P<0.01). Conclusion Combining rh-endostatin with chemotherapy was superior to chemotherapy alone in treatment of NSCLC in total efficiency rate and disease control rate.

ZHANG Qi, XIA Ai-jun. Meta-analysis of combining rh-endostatin with chemotherapy in treatment of NSCLC[J]. Journal of Pharmaceutical Practice and Service, 2010, 28(6): 451-455.
Citation: ZHANG Qi, XIA Ai-jun. Meta-analysis of combining rh-endostatin with chemotherapy in treatment of NSCLC[J]. Journal of Pharmaceutical Practice and Service, 2010, 28(6): 451-455.
shu

    HTML

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return